Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy – StreetInsider.com
|
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
StreetInsider.com Chardan Capital Markets initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $23.50. Analyst Madhu Kumar commented, "We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating … Crispr Therapeutics AG – Receive News & Ratings Daily Analysts Set $27.00 Target Price for Crispr Therapeutics AG (CRSP) Stock Analysts Favoring These Names: CRISPR Therapeutics AG (:CRSP) USD Partners LP (NYSE:USDP) |
